News
MSD’s blockbuster immunotherapy Keytruda has secured another FDA approval, this time for the treatment of hepatocellular carcinoma (HCC) in...
Food and Drug Administration (FDA) commissioner Scott Gottlieb has said that if a more rigorous approval process is introduced for opioids, the...
AstraZeneca has revealed new data for its sodium-glucose co-transporter 2 (SGLT2) inhibitor Farxiga (dapagliflozin) at the American Heart...
The UK government’s request that pharmaceutical companies stockpile an additional six weeks’ worth of medicine, in preparation for a no-deal Brexit...
Hundreds have died in a recent outbreak of Ebola in the Democratic Republic of Congo (DRC), in what has been described as the worst outbreak in the...
Eisai has revealed that its multireceptor Tyrosine Kinase Inhibitor Lenvima (lenvatinib) has been recommended by NICE, meaning it can now be used...
Check out this week’s top ten most popular stories on Pharmafile.com!
Britain’s cost effectiveness body the National Institute of Health and Care Excellence (NICE) has chosen not to recommend AstraZeneca’s Olaparib...
The NHS in England is now spending over £1billion a year on diabetes prescriptions, almost doubling in the last decade, according to NHS Digital.
The state of Alabama’s biggest insurer Blue Cross and Blue Shield will no long cover opioid painkiller OxyContin. The decision has come in response...
